Report

QuickView: Maintaining the rhythm

A strategic partnership with AliveCor and US (FDA 510k) and EU (CE mark) approvals for the mobile cardiac telemetry (MCT) patch kicks off an important year for LifeWatch. With a full turnaround of the company’s fortunes nearly complete, there is a renewed focus on growth via organic and external means. The recent purchase of FlexLife Health and suspension of its home sleep testing services are testament to LifeWatch’s new strategic direction.
Underlying
LifeWatch AG

Lifewatch is a specialist in telemedicine monitoring services and a developer, manufacturer and marketer of wireless healthcare technologies and products. These services and devices are used to assess a broad array of physiological functions that allow patients to be monitored and treated in their normal, everyday environment. Co.'s primary service offering is cardiac monitoring, as well as monitors for the following services: ACT, Event, Holter and Pacemaker. Co. functions in two business segments: Monitoring services and the sale of systems.

Provider
Edison Investment Research
Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

.

Other Reports on these Companies
Other Reports from Edison Investment Research

ResearchPool Subscriptions

Get the most out of your insights

Get in touch